SEC
CRSP icon

Seven Eight Capital’s CRISPR Therapeutics CRSP Stock Holding History

Seven Eight Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,524
Closed -$854K – 736
2024
Q1 		$854K Sell
12,524
-17,032
-58% -$1.22M 0.09% 332
2023
Q4 		$1.85M Buy
29,556
+13,377
+83% +$740K 0.21% 139
2023
Q3 		$734K Buy
+16,179
New +$836K 0.09% 309
2022
Q4 		– Sell
-8,362
Closed -$546K – 450
2022
Q3 		$546K Buy
+8,362
New +$606K 0.11% 258

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Seven Eight Capital's CRSP Position: Q2 2024 in Review

Seven Eight Capital sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 12,524 shares — an estimated $854K sold.

Seven Eight Capital first reported a position in CRSP in Q3 2022 and held it in 4 quarters. The position peaked at $1.85M in Q4 2023. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

  • Seven Eight Capital reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Seven Eight Capital sold 12,524 CRISPR Therapeutics shares in Q2 2024, an estimated $854K.
  • Seven Eight Capital first reported a position in CRISPR Therapeutics in Q3 2022 and held it in 4 quarters.
  • Seven Eight Capital's CRISPR Therapeutics position peaked at $1.85M in Q4 2023.
  • 449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on Seven Eight Capital's 13F filing for Q2 2024, filed 12 Aug 2024.